ATRC - AtriCure, Inc.

QQQ $ 432.26 $ -0.89 (-0.21 %)

DIA $ 383.12 $ -0.11 (-0.03 %)

SPY $ 509.87 $ -0.38 (-0.07 %)

TLT $ 88.91 $ 0.25 (0.28 %)

GLD $ 216.30 $ 0.17 (0.08 %)

Previous Close

$ 23.17

Open

$ 23.68

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 23.38 - $ 24.04

52 Week Range

$ 22.07 - $ 59.61

Volume

380,567

Average Volume

Market Cap

1.07B

Beta (5Y Monthly)

$ 1.37

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-16-2024	12-31-2023	10-K
2	11-02-2023	09-30-2023	10-Q
3	07-26-2023	06-30-2023	10-Q
4	05-03-2023	03-31-2023	10-Q
5	02-22-2023	12-31-2022	10-K
6	11-02-2022	09-30-2022	10-Q
7	08-03-2022	06-30-2022	10-Q
8	05-04-2022	03-31-2022	10-Q
9	02-17-2022	12-31-2021	10-K
10	11-04-2021	09-30-2021	10-Q
11	08-05-2021	06-30-2021	10-Q
12	04-28-2021	03-31-2021	10-Q
13	02-26-2021	12-31-2020	10-K
14	11-06-2020	09-30-2020	10-Q
15	07-29-2020	06-30-2020	10-Q
16	04-30-2020	03-31-2020	10-Q
17	02-24-2020	12-31-2019	10-K
18	10-31-2019	09-30-2019	10-Q
19	07-31-2019	06-30-2019	10-Q
20	04-26-2019	03-31-2019	10-Q
21	03-01-2019	12-31-2018	10-K
22	11-02-2018	09-30-2018	10-Q
23	08-02-2018	06-30-2018	10-Q
24	04-27-2018	03-31-2018	10-Q
25	02-28-2018	12-31-2017	10-K
26	11-02-2017	09-30-2017	10-Q
27	07-28-2017	06-30-2017	10-Q
28	05-05-2017	03-31-2017	10-Q
29	03-08-2017	12-31-2016	10-K
30	10-28-2016	09-30-2016	10-Q
31	08-05-2016	06-30-2016	10-Q
32	04-29-2016	03-31-2016	10-Q
33	02-29-2016	12-31-2015	10-K
34	10-30-2015	09-30-2015	10-Q
35	07-31-2015	06-30-2015	10-Q
36	05-01-2015	03-31-2015	10-Q
37	03-02-2015	12-31-2014	10-K
38	10-31-2014	09-30-2014	10-Q
39	07-30-2014	06-30-2014	10-Q
40	04-30-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Oppenheimer Upgrades AtriCure to Outperfor...
04/23/2024 11:40:45

Oppenheimer analyst Suraj Kalia upgrades AtriCure (NASDAQ:ATRC) from Perform to Outperform and announces $32 price target.

AtriCure Launched cryoSPHERE+ Cryoablation...
04/18/2024 12:08:32

Key Takeaways From AtriCure Analyst Ratings
04/10/2024 12:01:20

Needham Reiterates Buy on AtriCure, Mainta...
04/10/2024 09:34:11

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $46 price target.

Coinbase To Rally Around 45%? Here Are 10 ...
02/16/2024 13:30:24

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Cracking The Code: Understanding Analyst R...
02/16/2024 12:00:13

Needham Maintains Buy on AtriCure, Raises ...
02/16/2024 10:41:21

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $44 to $46.

Recap: AtriCure Q4 Earnings
02/15/2024 21:05:14

AtriCure Q4 2023 Adj EPS $(0.21) Beats $(0...
02/15/2024 21:03:40

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8...

Earnings Scheduled For February 15, 2024
02/15/2024 10:17:01

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

AtriCure's Earnings: A Preview
02/14/2024 15:01:57

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
01/18/2024 13:05:59

Key Takeaways From AtriCure Analyst Ratings
01/04/2024 12:00:54

Needham Maintains Buy on AtriCure, Lowers ...
01/04/2024 11:27:36

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $49 to $44.

JMP Securities Reiterates Market Outperfor...
11/29/2023 15:45:07

JMP Securities analyst Daniel Stauder reiterates AtriCure (NASDAQ:ATRC) with a Market Outperform and maintains $60 price tar...

Where AtriCure Stands With Analysts
11/29/2023 12:00:44

Needham Reiterates Buy on AtriCure, Mainta...
11/29/2023 09:31:56

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $49 price target.

Needham Says Medtronic Initiation Of Limit...
11/28/2023 19:32:54

JP Morgan Maintains Overweight on AtriCure...
11/02/2023 21:27:08

JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $60 to $50.

Needham Maintains Buy on AtriCure, Lowers ...
11/02/2023 10:32:30

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $68 to $49.